The leader will have the opportunity to collaborate closely with internationally recognized programs, including the Marc and Jennifer Lipschultz Precision Immunology Institute (PrIISM), the Human Immune Monitoring Center, and Mount Sinai's expanding programs in cancer immunotherapy, immunoprevention, and clinical trial innovation. Institutional priorities include advancing lung cancer immunoprevention, cancer interception, early detection, neoadjuvant and perioperative clinical trials, and precision immunotherapy, supported by Mount Sinai's internationally recognized strengths in pulmonology, precision immunology, cancer biology.